A Novel Single B-cell Based Platform SMab™ for Efficient Monoclonal Antibody Discovery
PRESENTER:
Dr. Hai Wu | CTO, Antibody Division | ABclonal Technology
PRESENTER'S BIO:
Hai Wu, Ph.D. is the chief technology officer, antibody division at ABclonal Technology. Dr. Wu co-developed the single-B-cell-based monoclonal antibody discovery technology, SMab™, which enables high-throughput development of high-affinity, high-specificity monoclonal antibodies. The resulting antibodies significantly surpasses those developsed using traditional technologies such as hybridoma and phage display. Antibody products generated using SMab™ have been widely adopted as research tools, diagnostics products, and therapeutic leads. Prior, Dr. Wu earned his Ph.D. in genetics from University of Rochester and completed his postdoctoral training at UMASS Medical School.
ABSTRACT:
ABclonal has developed a novel monoclonal antibody (mAb) discovery platform, SMab™ platform, based on single B-cell isolation, culture, and cloning. Using universal SMab™ platform, ABclonal can rapidly develop monoclonal antibodies from a panel of hosts including rabbit, llama, and human. Moreover, SMab™ platform has significantly shortened the monoclonal antibody screening process with greater diversity and efficiency. Coupled with unique biology of rabbit, ABclonal delivers the best-in-class rabbit monoclonal antibodies (RmAb) to our CRO clients. RmAbs have a collective of advantages over rodent mAbs: higher affinity, superior specificity, broader epitope recognition, better hapten recognition and greater stability. Our typical turnaround time is 3 - 4.5 months from immunization to final deliverables. We have served more than 80 industrial clients from biopharma, biotech, and IVD companies globally since 2016. The antibodies generated using SMab™ platform have been widely adopted as research tools, diagnostic products, preclinical studies, and therapeutic leads. Our established expertise on antigen design, monoclonal antibody screening, and antibody engineering makes ABclonal an excellent partner to address your mAb need.
Technology Platforms for Monoclonal Antibody Development and Production
PRESENTER:
Dr. Amy Sheng | Interim Head, CRO Program | Sino Biological
PRESENTER'S BIO:
Dr. Amy Sheng is a technical account manager at Sino Biological. Dr. Sheng joined Sino Biological in 2021 supporting CRO services and project management in the Eastern US region. Prior to joining Sino Biological, she worked in Caprico Biotechnologies as a production manager in charge of antibody development and production for flow cytometry. She has a Ph.D. in Molecular and Cell Biology from the Georgia Institute of Technology and is an ASCP-certified molecular biologist and ASQ-certified CSSGB.
ABSTRACT:
Monoclonal antibody (mAb) is generated from a single clone of an antibody-producing cell and recognizes one specific epitope. It has been known for its advantages of high specificity, sensitivity, batch-to-batch consistency, and scalability. Moreover, recombinant antibody engineering has brought a revolution to mAb production and tremendously expanded the applications to in vitro diagnostics and clinical uses for cancers, immune-deficiency diseases, viral infections, etc.
The webinar will focus on the development of mAb through hybridoma, phage display, and single B cell sorting techniques, as well as a discussion regarding mAb applications and R&D case studies.
Learning Objectives
1. Explain basic techniques of monoclonal antibody development
2. Illustrate applications of monoclonal antibodies
3. Discuss the future of antibody development
Copyright © 2025 LSE Virtual Events - All Rights Reserved.
The institution names listed are for invitation purposes only. In no way should it imply an existing relationship between LSE and that institution.